AI-pathology company Paige today announced it received an additional $15 million from Goldman Sachs, bringing its Series B funding round to $70 million. The previously announced round also included $5 million from and Healthcare Venture Partners, which added to its previous $10 million investment. Goldman Sachs had also invested $5 million in April. New York-based […]
FDA clears Therapixel’s Mammoscreen
Therapixel today said it received FDA 510(k) clearance for its MammoScreen artificial intelligence-used software. MammoScreen automatically detects and characterizes suspicious soft tissue lesions and calcifications in mammogram images while assessing malignancy. The results are then presented in a summary report that characterizes suspiciousness of lesions on a scale of 1 to 10, with one being […]
Cel-Sci raises $10m
Phase 3 cancer immunotherapy company Cel-Sci (NYSE:CVM) announced today that it raised approximately $10 million through the exercise of warrants. The Vienna, Va.-based company plans to use the funds to complete the expansion of its Multikine cancer immunotherapy manufacturing facility near Baltimore in anticipation of a biologics license application (BLA) submission and the subsequent effort to receive […]
Lantheus, Progenics complete merger
Lantheus Medical Imaging (NSDQ:LNTH) parent company Lantheus Holdings announced the completion of its merger with Progenics Pharmaceuticals. Progenics, an oncology company developing medicines and artificial intelligence-based technologies for finding, fighting and following cancer, entered into a merger agreement with Lantheus that was first announced on Oct. 2, 2019. Upon the completion of the merger, Progenics stockholders […]
Boston Scientific touts SpaceOAR meta-analysis results
Boston Scientific (NYSE:BSX) announced that published results from an analysis of its SpaceOAR hydrogel spacer revealed safe prostate-rectum separation. Marlborough, Mass.-based Boston Scientific has developed the SpaceOAR since its $600 million acquisition of Augmenix in September 2018. The absorbable polyethylene glycol hydrogel spacer won CE Mark approval in the European Union in 2010 and 510(k) clearance from the […]
Accuray launches CyberKnife S7 system
Accuray (NSDQ:ARAY) announced today that it launched its CyberKnife S7 system for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Using real-time artificial intelligence-driven motion tracking and synchronization, CyberKnife S7 offers treatments for SRS and SBRT in as little as 15 minutes, according to a news release. The system’s AI adapts radiation delivery to patient […]
Sirius Medical wins CE mark for non-radioactive localization system
Sirius Medical announced that it received CE Mark approval for its Sirius Pintuition non-radioactive tumor localization system. Eindhoven, the Netherlands-based Sirius said in a news release that it intends to launch the Pintuition system in September of this year, with the first systems currently in production. The company intends to implement the systems in hospitals […]
Support grows for return of medtech reps to hospitals
Twenty-six more medical and surgical societies and healthcare associations have endorsed guidelines for the safe return of medtech company representatives to healthcare facilities during the coronavirus pandemic. The guidance, released in May by AdvaMed, the Association of periOperative Registered Nurses (AORN) and the American Hospital Association (AHA), builds on the April 17 joint statement by AHA, […]
Lunit wins CE Mark for AI-based breast cancer detection software
Lunit announced today that it received CE Mark approval in Europe for its Lunit Insight MMG artificial intelligence-based software. Insight MMG uses AI to analyze mammography images and provide the location of lesions that are suspicious for breast cancer, along with an abnormality score that reflects the probability of the existence of detected lesions. According […]
RefleXion, Merck team up on late-stage cancer study
RefleXion announced today that it entered into a clinical collaboration with Merck to evaluate Merck’s (NYSE:MRK) Keytruda anti-PD-1 therapy in clinical trials. Hayward, Calif.-based therapeutic oncology company RefleXion is joining forces with Merck to evaluate Keytruda’s safety and efficacy in combination with RefleXion’s biology-guided radiotherapy (BgRT) in multiple late-stage cancers, including non-small cell lung cancer, in […]
Report: PerkinElmer under investigation for Medicare fraud
PerkinElmer (NYSE:PKI) is under federal scrutiny for alleged involvement in a scam to bill Medicare for tens of thousands of unnecessary genetic cancer tests, according to a report by Reuters. The news agency cited three unidentified sources and government documents linking the Waltham, Mass.-based diagnostic and scientific instrument company to the probe. PerkinElmer acknowledged that it has […]
- 1
- 2
- 3
- …
- 81
- Next Page »
